PDS Biotechnology PIPE targets ~$11.55M; Nant/AB $11M FDA milestone commitment
PDS Biotechnology said its private placement is expected to raise approximately $11.55 million at the initial closing. Nant and AB Group committed an additional $11 million milestone tranche upon FDA submission of a Phase 3 protocol for PDS0301.
55 million at the initial closing of a private placement, with an additional $11 million milestone tranche committed by Nant and AB Group if it submits a Phase 3 protocol for PDS0301 to the FDA. The PIPE includes common shares or pre-funded warrants, and the company said the arrangement relates to a Phase 3 protocol for PDS0301.